# Columbamine (from Rhizoma Coptidis / Coptis chinensis)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/columbamine-from-rhizoma-coptidis-coptis-chinensis
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** 2,3,9,10-tetraoxygenated protoberberine alkaloid, COL (abbreviation), Huanglian alkaloid fraction, isoquinoline alkaloid columbamine, calumba alkaloid

## Overview

Columbamine is a protoberberine isoquinoline alkaloid that induces apoptosis in cancer cells via caspase-3/PARP activation and suppresses tumor proliferation by inhibiting Wnt/β-catenin and HSP90/STAT3 signaling pathways. In acetylcholinesterase inhibition assays, columbamine demonstrated an IC50 of 2.29 ± 0.7 μg/mL, outperforming berberine (IC50 3.22 ± 0.9 μg/mL), positioning it as a candidate [neuroprotective](/ingredients/condition/cognitive) alkaloid in preclinical models.

## Health Benefits

- **Anticancer Activity (Colon)**: Columbamine induces apoptosis in HCT116 and LoVo colon cancer cell lines by increasing cleaved caspase-3, cleaved PARP, and BAD expression while downregulating the anti-apoptotic protein Bcl-2, effectively triggering programmed cell death through intrinsic caspase-dependent pathways.
- **Wnt/β-Catenin Pathway Suppression**: It downregulates key oncogenic effectors of the Wnt signaling cascade—including β-catenin, Dishevelled (DVL), cyclin D1, and c-Myc—in a dose- and time-dependent manner, thereby reducing transcriptional activity in TCF/LEF reporter assays relevant to colorectal and other epithelial cancers.
- **Melanoma Antiproliferative Effect**: In A375 melanoma cells, columbamine inhibits both proliferation and invasive capacity by inactivating STAT3 through an HSP90-mediated mechanism, disrupting a transcription factor central to cancer cell survival and metastatic progression.
- **Acetylcholinesterase (AChE) Inhibition**: Columbamine demonstrates potent AChE inhibitory activity with an IC50 of 2.29 ± 0.7 μg/mL and shows the strongest correlation with AChE inhibition in Coptis chinensis extracts via IncMSE and Boruta statistical analyses, suggesting a role in supporting cholinergic neurotransmission relevant to [cognitive function](/ingredients/condition/cognitive).
- **Hypolipidemic Effects**: Columbamine inhibits triglyceride and cholesterol biosynthesis in hepatocytes, contributing to lipid-lowering activity consistent with the traditional use of Coptis chinensis preparations for metabolic dysregulation, though precise molecular lipid metabolism targets require further elucidation.
- **[Anti-inflammatory](/ingredients/condition/inflammation) and Antioxidant Properties**: The alkaloid modulates inflammatory signaling and reduces [oxidative stress](/ingredients/condition/antioxidant) markers in preclinical models, with activity attributed partly to suppression of MAPK-related pathways (p38, ERK1/2), providing a mechanistic basis for traditional anti-inflammatory applications.
- **[Hepatoprotective](/ingredients/condition/detox) and Hypoglycemic Potential**: Columbamine exhibits hepatoprotective properties in cell-based models and contributes to hypoglycemic effects observed in Coptis chinensis alkaloid fractions, potentially through modulation of [glucose metabolism](/ingredients/condition/weight-management) pathways, though specific molecular targets for glycemic control remain under investigation.

## Mechanism of Action

Columbamine exerts its primary anticancer mechanism through caspase-dependent apoptosis induction: it upregulates pro-apoptotic proteins BAD and cleaved caspase-3/PARP while suppressing the anti-apoptotic Bcl-2, and concurrently inhibits the Wnt/β-catenin transcriptional program by reducing DVL, β-catenin nuclear accumulation, cyclin D1, and c-Myc expression as confirmed by TCF/LEF luciferase reporter assays. In melanoma, columbamine disrupts the HSP90 chaperone interaction that stabilizes STAT3, leading to STAT3 inactivation and downstream suppression of genes governing cell survival and invasion. The alkaloid also inhibits PI3K/AKT, p38 MAPK, and ERK1/2 signaling in hepatocellular carcinoma models, representing convergent suppression of multiple pro-survival kinase cascades. Its AChE inhibitory activity—likely mediated by the planar quaternary nitrogen structure of the protoberberine scaffold interacting with the enzyme's active-site gorge—further contributes to cholinergic modulation independent of its oncological mechanisms.

## Clinical Summary

No human clinical trials have been conducted specifically evaluating columbamine as an isolated therapeutic compound, meaning no clinical outcomes such as tumor response rates, [cognitive](/ingredients/condition/cognitive) endpoints, or lipid panel changes can be attributed to columbamine alone in human subjects. The compound's pharmacological properties have been characterized entirely through in vitro models, with the most quantitatively robust data point being its AChE IC50 of 2.29 ± 0.7 μg/mL and its apoptosis-inducing effects in colon and melanoma cell lines. While columbamine is a constituent of Rhizoma Coptidis preparations that have a broader traditional and some clinical evidence base, isolating its individual contribution to clinical outcomes in mixed-alkaloid extracts is methodologically challenging and has not been accomplished. Confidence in clinical benefit remains very low, and translation from preclinical findings to therapeutic application requires well-designed dose-escalation and efficacy trials in animal models followed by human studies.

## Nutritional Profile

Columbamine is a pure alkaloid compound rather than a nutritional ingredient, and therefore does not possess a conventional macronutrient or micronutrient profile. As a protoberberine-type isoquinoline alkaloid with the molecular formula C20H22NO4+ (as a quaternary ammonium salt), its pharmacological activity derives entirely from its aromatic ring system and cationic nitrogen, not from caloric or nutritional contribution. In the context of Rhizoma Coptidis as a whole-plant source, the rhizome contains total alkaloids estimated at 5–8% dry weight, with berberine as the dominant fraction; columbamine represents a minor but pharmacologically active constituent alongside coptisine, palmatine, epiberberine, and jatrorrhizine. Bioavailability of protoberberine alkaloids as a class is generally moderate to low due to first-pass hepatic [metabolism](/ingredients/condition/weight-management) and P-glycoprotein efflux, but specific oral bioavailability data for isolated columbamine in humans is not established.

## Dosage & Preparation

- **Traditional Decoction (Rhizoma Coptidis)**: Dried Coptis chinensis rhizome (3–9 g per day) boiled in water as a classical Chinese medicinal decoction; columbamine is co-extracted alongside berberine, coptisine, palmatine, epiberberine, and jatrorrhizine.
- **Standardized Herbal Extract (Huanglian)**: Commercial Coptis chinensis extracts are typically standardized to total alkaloid content (commonly 5–10% berberine equivalents); columbamine fraction is not independently standardized in available commercial products.
- **Purified Alkaloid (Research Grade)**: Used in in vitro studies as isolated powder dissolved in DMSO or aqueous buffer; no established human supplemental dose exists due to absence of clinical trial data.
- **Capsule/Tablet (Mixed Alkaloid Formulas)**: Available as part of combination Chinese herbal formulations; individual columbamine content per dose is not typically disclosed on labeling.
- **Effective Dose Range**: No clinically validated dose range has been established; in vitro concentrations used in cell studies do not directly translate to oral supplemental doses without pharmacokinetic bridging data.
- **Timing**: No evidence-based timing recommendations exist; traditional Coptis rhizome preparations are typically administered with meals to minimize gastrointestinal irritation.

## Safety & Drug Interactions

Columbamine is characterized in preclinical anti-osteosarcoma literature as exhibiting minor side effects with favorable tolerability compared to conventional chemotherapeutics, and [hepatoprotective](/ingredients/condition/detox) and [neuroprotective](/ingredients/condition/cognitive) properties observed in cell-based models further support a tentatively low-toxicity profile; however, the absence of formal in vivo toxicology studies or human safety data means definitive safety conclusions cannot be drawn. As a structurally related protoberberine alkaloid sharing the Coptis chinensis matrix with berberine, potential drug interactions relevant to berberine—including inhibition of CYP2D6 and CYP3A4 enzymes and potentiation of hypoglycemic agents—may be extrapolated cautiously but have not been independently confirmed for columbamine. No maximum safe dose, contraindications specific to columbamine, or gestational safety data are established; pregnancy and lactation use should be avoided given the absence of safety evidence and the known uterotonic potential of related protoberberine alkaloids. Individuals taking anticoagulants, antidiabetic medications, or immunosuppressants should exercise caution with Coptis-containing preparations until interaction studies specific to columbamine are conducted.

## Scientific Research

All available evidence for columbamine is exclusively preclinical, derived from in vitro cell line experiments; no human clinical trials, animal pharmacokinetic studies, or Phase I/II oncology trials are reported in the peer-reviewed literature to date. Key studies include flow cytometry and Western blot analyses in HCT116, LoVo, and SW480 colon cancer cell lines demonstrating apoptosis induction, and TCF/LEF reporter assays quantifying Wnt pathway suppression in a dose- and time-dependent manner. AChE inhibitory potency was quantified with a reported IC50 of 2.29 ± 0.7 μg/mL using purified enzyme assays, and multivariate chemometric analyses (IncMSE, Boruta) identified columbamine as the principal AChE-inhibiting alkaloid in Coptis chinensis extracts. The overall body of evidence is limited in translational value due to the absence of in vivo pharmacokinetic data, human bioavailability assessments, and any controlled clinical investigations, rendering all biological claims preliminary.

## Historical & Cultural Context

Columbamine was first described in scientific literature as an alkaloid constituent of calumba root (Jateorhiza palmata), a plant used in East African and European traditional medicine since at least the 18th century as a bitter tonic for digestive complaints, fevers, and as an antimalarial remedy. In Traditional Chinese Medicine (TCM), its primary botanical source, Coptis chinensis (Huanglian), has been employed for over two millennia, referenced in foundational texts including the Shennong Bencao Jing, primarily for clearing heat and dampness, treating dysentery, reducing [inflammation](/ingredients/condition/inflammation), and managing conditions attributed to excess internal fire. Rhizome preparations of Coptis were traditionally administered as decoctions, powders, or combined with other herbs in classical formulas such as Huanglian Jiedu Tang (Coptis Decoction to Relieve Toxicity), used for infections, gastrointestinal infections, and [cardiovascular](/ingredients/condition/heart-health)-metabolic conditions. The multi-alkaloid synergy in traditional preparations was empirically optimized over centuries before the individual contribution of columbamine to pharmacological activity was recognized through modern phytochemical isolation techniques.

## Synergistic Combinations

Within Rhizoma Coptidis extracts, columbamine co-occurs with palmatine (IC50 1.49 ± 0.4 μg/mL for AChE) and berberine (IC50 3.22 ± 0.9 μg/mL), and the combined alkaloid fraction demonstrates stronger AChE inhibition than individual constituents alone, suggesting additive or synergistic cholinergic modulation within the natural extract matrix. Berberine and columbamine share convergent oncogenic pathway targets—Wnt/β-catenin and MAPK suppression—and their co-administration in mixed alkaloid fractions may provide complementary apoptosis-inducing activity across multiple cancer signaling nodes, though formal combination index studies have not been published. In traditional TCM formulations, Coptis chinensis is frequently paired with Scutellaria baicalensis (Huangqin), whose flavonoids (baicalein, wogonin) may enhance [anti-inflammatory](/ingredients/condition/inflammation) synergy through complementary NF-κB and COX-2 inhibition alongside columbamine's MAPK suppression.

## Frequently Asked Questions

### What is columbamine and where does it come from?

Columbamine is a protoberberine-type isoquinoline alkaloid first isolated from calumba root (Jateorhiza palmata) and most commonly extracted from the rhizome of Coptis chinensis (Huanglian), a traditional Chinese medicinal herb. It belongs to the same structural class as berberine, coptisine, and palmatine, which co-occur in Coptis rhizome preparations. Commercially, it is obtained through phytochemical isolation of Coptis chinensis extracts and is used primarily as a research compound rather than a standalone supplement.

### Does columbamine have proven anticancer effects in humans?

No human clinical trials evaluating columbamine as an anticancer agent have been published; all current evidence is derived from in vitro studies using colon cancer cell lines (HCT116, LoVo, SW480) and melanoma cells (A375). In these models, columbamine induces apoptosis by activating caspase-3 and PARP cleavage, suppressing Bcl-2, and blocking Wnt/β-catenin and HSP90/STAT3 signaling pathways. While these mechanisms are pharmacologically meaningful, translation to clinical efficacy in human cancer patients remains entirely undemonstrated.

### How does columbamine compare to berberine for acetylcholinesterase inhibition?

In standardized AChE inhibition assays using purified enzyme, columbamine demonstrated an IC50 of 2.29 ± 0.7 μg/mL, which is superior to berberine's IC50 of 3.22 ± 0.9 μg/mL but slightly less potent than palmatine at 1.49 ± 0.4 μg/mL. Chemometric analyses using IncMSE and Boruta feature selection identified columbamine as the alkaloid most strongly correlated with AChE inhibitory activity in Coptis chinensis extracts. This suggests that columbamine may contribute disproportionately to the neuroprotective activity attributed to Huanglian preparations relative to its concentration.

### Is columbamine safe to take as a supplement?

Formal safety data for columbamine as an isolated oral supplement in humans does not currently exist, as no clinical trials or phase I toxicology studies have been conducted. Preclinical characterizations describe it as having minor side effects and favorable tolerability compared to conventional chemotherapy agents, and its structural analogs in Coptis chinensis (particularly berberine) have a well-established safety record at low-to-moderate doses. Until human pharmacokinetic and safety studies are completed, columbamine should not be self-administered as an isolated supplement, and individuals with diabetes, liver conditions, or those taking prescription medications should consult a healthcare provider before using Coptis-containing products.

### What traditional medicine systems use columbamine-containing plants?

Columbamine's primary plant source, Coptis chinensis, has been used in Traditional Chinese Medicine for over 2,000 years, documented in the Shennong Bencao Jing as a treatment for inflammatory conditions, dysentery, and febrile diseases attributed to internal heat and dampness. It features in classical TCM formulas such as Huanglian Jiedu Tang and Zuojin Wan, administered as rhizome decoctions or powders. Independently, calumba root—another columbamine source—was used in East African and 18th–19th century European botanical medicine as a bitter digestive tonic and antimalarial remedy.

### What is the evidence for columbamine's effects on colon cancer cells?

Research demonstrates that columbamine induces apoptosis in colon cancer cell lines (HCT116 and LoVo) by activating intrinsic caspase-dependent pathways, increasing cleaved caspase-3 and PARP while suppressing the anti-apoptotic protein Bcl-2. These in vitro findings show columbamine triggers programmed cell death through BAD expression upregulation, though human clinical trials remain limited. The evidence is promising for mechanistic research but cannot yet be extrapolated to clinical efficacy in patients.

### Does columbamine interact with common medications?

Columbamine shares structural similarities with berberine and may inhibit cytochrome P450 enzymes, potentially affecting metabolism of drugs like statins, anticoagulants, and antihistamines. Limited direct interaction studies exist for columbamine specifically, making it prudent to consult a healthcare provider before combining with prescription medications. The alkaloid's hepatic metabolism suggests caution with drugs requiring liver enzyme processing.

### Who should avoid columbamine supplementation?

Columbamine should be avoided by pregnant women and nursing mothers due to insufficient safety data for fetal development and breast milk transfer. Individuals with liver disease or those taking multiple medications metabolized by the liver should consult healthcare providers, as columbamine's hepatic processing may pose risks. People with bleeding disorders may also need to avoid this ingredient due to potential interactions with hemostasis pathways.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*